RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 4, 2008, Pages 625-632

  Lodish, Maya B ^a   Stratakis, Constantine A ^b  

^a Department of Pediatric Endocrinology   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Clinical trial; Multiple endocrine neoplasia; Oncogene; Thyroid cancer; Tyrosine kinase inhibitor

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; APTAMER; AXITINIB; BEVACIZUMAB; BISPECIFIC ANTIBODY; BORTEZOMIB; CAPECITABINE; CEP 751; DACARBAZINE; DIPENTETIC ACID I 131; GEFITINIB; IMATINIB; IRINOTECAN; LESTAURTINIB; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PENTETREOTIDE IN 111; PLACEBO; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RPI 1; SORAFENIB; SUNITINIB; TANESPIMYCIN; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; XL 184; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN;

AUTOSOMAL DOMINANT INHERITANCE; CANCER RADIOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE ACTIVATION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERTENSION; MONOTHERAPY; NAUSEA; NEUROFIBROMATOSIS; PATHOPHYSIOLOGY; PREDICTION; PROTO ONCOGENE; QT PROLONGATION; RADIOIMMUNOTHERAPY; REVIEW; SIPPLE SYNDROME; STEADY STATE; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; DRUG ANTAGONISM; GENETICS; GENOTYPE; MEDULLARY CARCINOMA; METABOLISM; MORTALITY; MUTATION; PHENOTYPE; SURVIVAL RATE; THYROID TUMOR;

CARCINOMA, MEDULLARY; GENOTYPE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 43049161065     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.4.625     Document Type: Review

References (67)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10-30, (2005).
2. Kouvaraki MA, Shapiro SE, Perrier ND et al. RET proto-oncogene, a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15(6), 531-544 (2005).
3. Block MA, Jackson CE, Greenawald KA, Yott JB, Tashjian AH Jr. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch. Surg. 115(2), 142-148 (1980).
4. Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658-5671 (2001).
5. Farndon JR, Leight GS, Dilley WG et al. Familial medullary thyroid carcinoma without associated endocrinopathies, a distinct clinical entity. Br. J. Surg. 73(4), 278-281 (1986).
6. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med. 353(11), 1105-1113 (2005).
7. Ponder BA, Ponder MA, Coffey R et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1(8582), 397-401 (1988).
8. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma, clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 (5), 1139-1148 (2000).
9. Quayle FJ, Moley JF. Medullary thyroid carcinoma, including MEN 2A and MEN 2B syndromes. J. Surg. Oncol. 89(3), 122-129 (2005).
10. Vu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73(2), 432-436 (1994).
11. Di Bartolomeo M, Bajetta E, Bochicchio AM et al. A Phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (ITMO) Group. Ann. Oncol. 6(1), 77-79 (1995).
12. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br.J. Cancer 83(6), 715-718 (2000).
13. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer, analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6(4), 305-310 (1996).
14. Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma, results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin. Endocrinol. 48(3), 265-273 (1998).
15. Hundahl SA, Fleming ID, Frenigen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US 1985-1995 Cancer 83(12), 2638-2648 (1998).
16. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma, demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107(9), 2134-2142 (2006).
17. Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2(7), 851-856 (1993).
18. Mulligan LM, Kwok JB, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363(6428), 458-460 (1993).
19. Carlson KM, Dou S, Chi D et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl Acad Sci. USA 91(4), 1579-1583 (1994).
20. Wells SA Jr, Chi DD, Toshima K et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 220(3), 237-247 (1994).
21. Skinner MA. Management of hereditary thyroid cancer in children. Surg. Oncol. 12(2), 101-104 (2003).
22. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42(2), 581-588 (1985).
23. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 16(4-5), 441-467 (2005).
24. Drosten M, Putzer BM. Mechanisms of disease, cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat. Clin. Pract. Oncol. 3(10), 564-574 (2006).
25. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett. 204(2), 197-211 (2004).
26. Schuringa JJ, Wojtachnio K, Hagens W et al. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20(38), 5350-5358 (2001).
27. Ball DW. Medullary thyroid cancer, therapeutic targets and molecular markers. Curr. Opin. Oncol. 19(1), 18-23 (2007).
28. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367(6461), 380-383 (1994).
29. Eng C, Clayton D, Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276(19), 1575-1579 (1996).
30. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell Biol. 15(3), 1613-1619 (1995).
31. Santoro M, Carlomagno F, Romano A et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267(5196), 381-383 (1995).
32. Salvatore D, Melillo RM, Monaco C et al. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res. 61(4), 1426-1431 (2001).
33. Ren R. Mechanisms of BCR-ABL in the pathogenesis of CML. Nature Rev. Cancer 5(3) 172-183 (2005).
34. Cuccuru G, Lanzi C, Cassinelli G et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J. Natl Cancer Inst. 96(13), 1006-1014 (2004).
35. Strock CJ, Park JI, Rosen DM et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J. Clin. Endocrinol. Metab. 91(1), 79-84 (2006).
36. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Yandetanib (ZD6474), an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin. Investig. Drugs 16(2), 239-249 (2007).
37. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62(24), 7284-7290 (2002).
38. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ et al. A Phase II trial ofimatinib therapy for metastatic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 92(9), 3466-3469 (2007).
39. You YN, Lakhani V, Wells SA Jr. New directions in the treatment of thyroid cancer. J. Am. Coll Surg. 205(Suppl.4), S45-S48 (2007).
40. Wells SA, Gosnell, JE, Gagel RF et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label Phase II trial. ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol. 25(Suppl.18),(2007) (Abstract 6018).
41. Sherman SI, Angelos P, Ball DW et al. Thyroid carcinoma. J. Natl. Compr. Canc. Netw. 5(6), 568-621 (2007).
42. Williams D. Cancer after nuclear fallout, lessons from the Chernobyl accident. Nat. Rev. Cancer 2(7), 543-549 (2002).
43. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat Cancer. 12(2), 245-262 (2005).
44. Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst. 98(5), 326-334 (2006).
45. Carlomagno F, Guida T, Anaganti S et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23(36), 6056-6063 (2004).
46. Kober F, Hermann M, Handler A, Krotia G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(Suppl.18) (2007) (Abstract 14065).
47. Mitsiades CS, McMillin D, Kotoula V et al. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol Metab. 91(10), 4013-4021 (2006).
48. Cerchia L, Duconge F, Pestourie C et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 3(4), E123 (2005).
49. Mauro MJ. Defining and managing imatinib resistance. Hematology 1, 219-225 (2006).
50. Cerchia L, Libri D, Carlomagno MS, De F. The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret. Biochem J. 372(Part 3), 897-903 (2003).
51. Drosten M, Stiewe T, Putzer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther. 14(10), 971-982 (2003).
52. Plosker GL, Keam SJ. Trastuzumab, a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66(4), 449-475 (2006).
53. Yano L, Shimura M, Taniguchi M et al. Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase, Hum. Gene Ther. 11 (7), 995-1004 (2000).
54. Salvatore G, Nagata S, Billaud M, Santoro M, Vecchio G, Pastan I. Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. Biochem. Biophys. Res. Commun. 294(4), 813-817 (2002).
55. Corti A, Ponzoni M. Tumor vascular targeting with tumor necrosis factor α and chemotherapeutic drugs. Ann. NY Acad Sci. 1028,104-112 (2004).
56. Chow LQ, Eckhardt SG. Sunitinib, from rational design to clinical efficacy. J. Clin. Oncol. 25(7), 884-896 (2007).
57. Salgia R, Hong DS, Camacho LH et al. A Phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL 184, a VEGFR and MET kinase inhibitor, administered orally to patients with advanced malignancies. ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol. 25 (Suppl. 18) (2007) (Abstract 14031).
58. Sherman SI, Schlumberger MJ, Droz J et al. Initial results from a Phase II trial of motesnab diphosphate (AMG 766) in patients with differentiated thyroid cancer (DTC). ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol. 25 (Suppl. 18) (2007) (Abstract 6017).
59. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25(17), 2369-2376 (2007).
60. Pennell NA, Daniels GH, Haddad RI et al. A Phase II study of gefitinib in patients with advanced thyroid cancer. ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol. 25(Suppl.18) (2007) (Abstract 6020).
61. Salnikov AV, Heldin NE, Stuhr LB et al. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int. J. Cancer 119(12), 2795-2802 (2006).
62. Cohen EE, Vokes EE, Rosen LS et al. A Phase II study of axitinib (AG-013736 [AG] in patients with advanced thyroid cancers. ASCO Annual Meeting Proceedings Part 1. J. Clin Oncol. 25(Suppl.18), Abstract 6008 (2007).
63. 111 in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl. Med 44(1), 1-6 (2003).
64. Xiao L, Lu X, Ruden DM. Effectiveness of hsp90 inhibitors as anti-cancer drugs. Mini Rev. Med. Chem. 6(10), 1137-1143 (2006).
65. Vaishampayan UN, Sausville EA, Horiba MN et al. Phase I trial of intravenous 17-allylaminogeldanamycin (A) and oral sorafenib (B) in pretreated advanced malignancy: plasma Hsp90 induction correlates with clinical benefit. J. Clin. Oncol 25(Suppl.18) (2007) (Abstract 3531).
66. Murgo AJ, Kummar S, Gardner ER et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly. J. Clin. Oncol. 25(Suppl. 18) (2007) (Abstract 3566).
67. Chatal JF, Campion L, Kraeber-Bodere F et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted and-carcinoembryonic-antigen radioimmunotherapy, a collaborative study with the French Endocrine Tumor Group. J. Clin Oncol. 24(11), 1705-1711 (2006).